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A b s t r a c t
Background: Colorectal cancer (CRC) is the second most common cancer in women and the third in men in Poland. The 
role of chemotherapy (CTX) depends on the stage of CRC: adjuvant CTX is a standard treatment in stage III and should also 
be considered in stage II with risk factors. 
Aim: The aim of the paper was to assess the cardiovascular consequences of CTX in CRC enrolled to the ONCOECHO 
multicentre study (2012–2014). To identify potential cardiotoxicity, we focused on myocardial function, heart rhythm and 
conduction disorders, and adverse cardiovascular events. 
Methods: Twenty-five CRC patients (12 women, mean age 61.3 [35–76] years), all receiving six-month adjuvant CTX were 
included. Thirteen patients received 5-fluorouracil (5FU)-based CTX, and 12 patients received a capecitabine-based scheme. 
Subjects were assessed at baseline and followed-up three, six, and 12 months after the onset of treatment. In this analysis 
we focused on conduction abnormalities, systolic and diastolic function of the left ventricle (LV), and cardiovascular events.
Results: In 12-month follow-up a decrease of selected tissue Doppler parameters (e.g. S’IVS, S’lat, and E’sept) was observed, 
and it was significant. LV structural parameters and ejection fraction (EF) remained unaffected. Changes in myocardial 
performance were not influenced by CTX regimen or treatment with beta-blockers or angiotensin-converting enzyme 
inhibitors. CTX did not affect LV structural parameters, EF, or conduction system, nor was it associated with cardiovascular 
events during the 12-month follow-up.
Conclusions: CTX in CRC patients does not affect LV structural parameters and EF. It may, however, trigger subtle changes 
in myocardial performance detectable by tissue Doppler echocardiography after 12 months. Moreover, it causes a transient 
increase of QT, which resolves after CTX cessation.
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INTRODUCTION
Colorectal cancer (CRC) is one of the most prevalent neo-
plastic disorders in the world. In Poland it is the second most 
common cancer in women and the third in men. According 
to the National Registry of the Oncology Institute in Warsaw, 
there were 17,450 newly diagnosed cases and 11,296 deaths 
due to CRC in Poland in 2013 [1]. In comparison to other 
countries the morbidity rate of CRC in Poland is moderate, but 
the diagnosis is often established late, with metastatic lesions 
already present in approximately 25% of patients. Symp-
toms of CRC depend on its localisation and phase. Different 
systems of classifications have been developed to stage the 
disease. Chronologically, they were the Dukes’ classification, 
with later modification by Astler-Coller (MAC, The Modified 
Astler-Coller Classification) and, currently recommended by 
the Union for International Cancer Control/American Joint 
Committee on Cancer (UICC/AJCC), the Tumour-Node-Me-
tastasis (TNM) classification (presently the seventh edition 
from 2010) [2].
The role of chemotherapy (CTX) depends on the stage 
of CRC. Adjuvant CTX is a standard treatment in stage III and 
should also be considered in stage II with risk factors, i.e. T4, 
number of excised lymph nodes < 12, urgent surgery, and/or 
infiltration of vessels [3, 4].
The aim of this paper was to assess the cardiovascular 
consequences of CTX due to CRC among the patients en-
rolled to the ONCOECHO multicentre study in the years 
2012–2014. To identify potential cardiotoxicity, we focused 
on the cardiac conduction and myocardial function but clinical 
cardiovascular events were also recorded. To the best of our 
knowledge this is the first publication to document subclinical 
systolic myocardial dysfunction using tissue Doppler echocar-
diography in a CRC population receiving CTX.
Study group
The study population comprised 25 CRC patients (12 women, 
mean age 61.3 ± 10.5, range 35–76 years) from three cen-
tres. Histologically, diagnosis of adenocarcinoma (with mu-
cinous adenocarcinoma in three cases) was established in all 
cases (in 52% of cases of moderate differentiation — G2). The 
lesion was located in the caecum (three patients), ascending 
colon (four patients), hepatic flexure (two patients), transverse 
colon (three patients), splenic flexure (two patients), sigmoid 
colon (four patients), rectosigmoid junction (one patient), and 
rectum (six patients). At the moment of diagnosis 56.2% of 
tumours were histologically classified as MAC B2.
Exclusion criteria included baseline left ventricular ejec-
tion fraction (LVEF) < 55%, regional wall motion abnormalities 
at rest, myocardial hypertrophy (any LV segment thicker than 
13 mm), moderate or severe valvular heart disease, and history 
of CTX or radiotherapy prior to the CRC diagnosis.
All patients received six-month adjuvant CTX. The most 
common scheme (applied in 12 patients) was LF1 (six cycles 
of five-day intravenous administration of 5-fluorouracil [5-FU] 
and leucovorin over six months). The other nine patients 
were treated according to the XELOX scheme (infusion of 
oxaliplatin combined with orally administered capecitabine 
per 14 days, cycles repeated every 21 days). Three patients 
underwent 14-day monotherapy with capecitabine repeated 
every 21 days. Finally, in one patient the FOLFIRI scheme was 
applied (48-h infusion of 5-FU with irinotecan and calcium 
folinate or levofolinic acid repeated every 14 days).
METHODS
Medical history, physical examination, and following addi-
tional tests were scheduled at baseline (before CTX adminis-
tration) and again after three, six, and 12 months, including:
Resting electrocardiogram (ECG) — assessment of rhythm 
origin and frequency, presence of arrhythmia and conduction dis-
orders, QT interval duration, ST segment, and T wave morphology.
Transthoracic echocardiography (TTE) — assessment of LV 
systolic and diastolic function, size and function of right ven-
tricle (RV), valvular function, presence of pericardial effusion, 
and additional intracardiac structures. TTE was performed by 
experienced echocardiographers with a Vivid 9 ultrasound 
system (GE). The following measurements were made accord-
ing to American Society of Echocardiography (ASE) [5] and 
the Section of Echocardiography of Polish Cardiac Society (SE 
PTK) [6, 7] recommendations:
 — left ventricular end-diastolic dimension (LVEDD);
 — left ventricular end-systolic dimension (LVESD);
 — intraventricular septum dimension in diastole (IVSDd);
 — posterior wall dimension in diastole (PWDd);
 — left atrial area (LAarea) in apical four-chamber view;
 — left atrial volume index (LAVI) calculated in apical four-
-chamber view according to Simpson’s rule;
 — LVEF according to simplified Simpson’s rule;
 — maximum systolic septal and lateral mitral annulus veloci-
ties (S’IVS, S’lat);
To assess LV diastolic function evaluation, we measured:
 — maximum early-diastolic septal and lateral mitral annulus 
velocity (E’sept, E’lat);
 — maximum early-diastolic filling velocity (E);
 — E/E’ ratio;
 — isovolumetric relaxation time.
Laboratory tests included peripheral blood morphology, 
lipidogram, serum fasting glucose level, serum transaminases 
activity, and serum creatinine concentration/glomerular filtra-
tion rate.
Deaths, myocardial infarctions, heart failure, and un-
planned cardiovascular hospitalisation during the 12-month 
follow-up were considered major adverse cardiovascular 
events (MACE).
Statistical analysis
Numerical variables were presented as arithmetic mean 
values with standard deviation when normally distributed or 
as median with interquartile range for non-normal distribu-
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tions. Significance of differences was verified with paired 
Student’s t-test (for related variables) or regular Student’s t-test 
(for comparison of two groups). Categorical variables were 
presented as absolute or relative frequency.
Hypotheses were verified at a significance level of 
p < 0.05 with two-sided testing. Statistical analysis was 
performed with SAS 9.2 (SAS Institute Inc., Cary NC, USA, 
2008) software.
RESULTS
Clinical data, laboratory and ECG findings
Cardiovascular risk factors and concomitant diseases identified 
in 25 CRC patients are presented in Table 1. Due to these 
reasons, prior to CTX patients were receiving angiotensin 
converting enzyme inhibitors (ACEI; n = 7), diuretics (n = 6), 
beta-blockers (n = 4), and oral anticoagulant (n = 1).
Baseline biochemistry was normal except for mildly 
lower concentration of haemoglobin (Table 2). No changes 
in blood pressure (BP), heart rate, and QT interval duration 
were noted after 12 months of follow-up (Table 3). Interest-
ingly, QT tended to be increased as soon as in the third month 
of observation and a significant prolongation was registered 
after six months (up to 392 ± 30 ms, p = 0.016); after CTX 
cessation QT returned to baseline at the 12th month (Table 4). 
Neither arrhythmia nor conduction disorders were observed 
throughout the study.
Echocardiography findings
Transthoracic echocardiography measurements after three 
months from CTX initiation did not differ from baseline. At 
six-month follow-up a minor increase in PWDd (p < 0.03) 
and a decrease in S’IVS (7.5 ± 1.2 cm/s vs. 8.7 ± 1.73 cm/s, 
p < 0.001) were observed. 
Mean values of TTE parameters at baseline and after 
12 months from CTX initiation are presented in Table 5. In 
12-month follow-up a decrease of both S’IVS and S’lat was 
significant. At the same time point a significant decrease of 
E’sept was noted, which was not observed six months earlier. 
PWDd after 12 months returned to baseline value after a tran-
sient increase was noted, as stated above, after six months. No 
MACEs occurred during the 12-month follow-up.
We compared the TTE parameters listed in Table 5 be-
tween the subgroups of patients who received ACEI and/or 
beta-blockers due to cardiologic indications before CTX initia-
tion (n = 10) with those who did not (n = 15) — no statistically 
significant differences were detected.
There were no significant differences in echocar-
diographic parameter values between patients who received 
5-FU/leucovorin-based chemotherapy (n = 13) and patients 
treated with capecitabine-based CTX (n = 12), neither at the 
beginning of the study nor after 12 months.
DISCUSSION
Cancer has grown to become a major epidemic of the 21st 
century. Gradually, as diagnosis is established earlier and 
treatment efficacy improves, the life expectancy of patients 
is increasing. Frequent cardiovascular comorbidity warrants 
Table 1. Cardiovascular risk factors and concomitant diseases 
in 25 colorectal cancer patients
Cardiovascular risk factor/ 
/concomitant disease
N (%)
Arterial hypertension 13 (52.0%)
Diabetes 4 (16.0%)
Hypercholesterolaemia 7 (28.0%)
Tobacco smoking 15 (60.0%)
Family history of cardiovascular disease 8 (32.0%)
Family history of oncologic disorder 17 (68.0%)
Stroke 1 (4.0%)
Table 2. Selected laboratory findings in colorectal cancer 
patients
Parameter Mean baseline value
Haemoglobin [mmol/L] 8.7 ± 2.3
Haematocrit [%] 37.8 ± 5.1
MCV [fL] 85.6 ± 6.7
MCHC [mmol/L] 23.6 ± 5.8
Erythrocytes [T/L] 4.42 ± 0.55
Leukocytes [G/L] 7.0 [6.6–9.6]
Platelets [G/L] 299 [262–368]
Glucose [mg%] 111 ± 37
Aspartate transaminase [U/L] 17.5 [15.0–19.0]
Alanine transaminase [U/L] 15.0 [13.0–26.0]
Creatinine [mg%] 0.81 [0.68–0.88]
MCV — mean corpuscular volume of erythrocyte; MCHC — mean 
corpuscular haemoglobin concentration in erythrocyte
Table 3. Blood pressure (BP) and heart rate at baseline and 
after 12 months from chemotherapy initiation in colorectal 






Systolic BP [mm Hg] 129 ± 9.7 127 ± 13.6 0.47
Diastolic BP [mm Hg] 82 ± 8.6 79 ± 11.6 0.10
Heart rate [bpm] 76 ± 12.9 71.8 ± 10.6 0.09
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involvement of a cardiologist in the managing team. Optimis-
ing oncologic and cardiovascular pharmacotherapy to max-
imise effectiveness and reduce side effects poses a challenge 
for both groups of specialists. 5-FU, a standard treatment 
of CRC, is known potentially to exert adverse influence on 
cardiovascular system. The presented study was aimed to 
assess the function of conduction system and myocardial 
performance in patients undergoing CTX during 12 months 
of follow-up. Reports on CTX cardiotoxicity in CRC patients 
are scarce. We believe our paper is the first one to document 
subtle, subclinical myocardial dysfunction by tissue Doppler 
in this cohort of patients.
We analysed 25 CRC patients in whom a histologic di-
agnosis of adenocarcinoma was uniformly established. The 
rectum was the most frequent location of the index lesion. 
Patients were treated according to CTX schemes containing 
5-FU or capecitabine. The number of patients included in 
this analysis is comparable to that in the scarce, previously 
published reports [8, 9]. 
Echocardiography findings at baseline were within cur-
rently recommended reference ranges [10] except for a minor 
increase in septal wall thickness (IVSDd of 11.1 ± 0.9 mm) 
and a decrease in S’IVS. 
Throughout the 12 months of follow-up LVEF remained nor-
mal (non-significant change from 65.9 ± 5.7% to 64.4 ± 6.4%). 
LVEDD and LVESD during CTX were slightly larger and returned 
to baseline values after 12 months. There was, however, 
a significant worsening in LV functional parameters by tissue 
Doppler. After a year from CTX initiation E’sept decreased 
from 7.29 ± 2.13 cm/s to 6.21 ± 2.19 cm/s, p = 0.02. Fur-
thermore, concurrently both S’IVS and S’lat have dropped 
from 8.7 ± 1.73 cm/s to 7.0 ± 0.91 cm/s, p < 0.0001 and 
from 10.24 ± 2.48 cm/s to 9.23 ± 1.12 cm/s, p = 0.03, re-
spectively. No other meaningful changes were identified by TTE 
after 12 months. The authors believe that this is the first report 
on subclinical LV dysfunction in CRC patients undergoing CTX.
In the existing literature, Balloni et al. [8] reported classic 
two-dimensional echocardiographic indices of LV function in 
Table 4. QT interval duration at baseline, three, six, and 12 months after chemotherapy initiation in colorectal cancer patients 
(mean ± standard deviation)
Parameter Baseline After 3 months After 6 months After 12 months 
QT interval [ms] 372 ± 31.7 384 ± 34 392 ± 30* 364 ± 25.7
*p < 0.05 vs. baseline
Table 5. Echocardiography findings at baseline and after 12 months of follow-up (mean ± standard deviation)
Parameter Baseline value After 12 months P
LVEDD [mm] 47.7 ± 5.3 48.4 ± 5.0 0.44
LVESD [mm] 30.0 ± 5.6 30.9 ± 5.5 0.46
LVEDV [mL] 102.8 ± 28.6 92.6 ± 23.9 0.17
LVESV [mL] 35.7 ± 12.7 33.3 ± 10.1 0.34
SV [mL] 67.1 ± 17.6 59.3 ± 16.0 0.14
Ejection fraction 4ch [%] 65.9 ± 6.0 64.5 ± 6.1 0.31
Left atrial area [cm2] 16.9 ± 5.0 17.0 ± 3.3 0.92
LAVI [mL/m2] 27.5 ± 10.4 26.3 ± 7.2 0.63
E’sept [cm/s] 7.29 ± 2.13 6.21 ± 2.19 0.02
E’lat [cm/s] 9.75 ± 3.31 9.00 ± 2.22 0.42
E [cm/s] 67.6 ± 18.4 65.5 ± 15.0 0.70
Isovolumetric relaxation time [ms] 98.4 ± 13.9 102.4 ± 17.0 0.47
S’IVS [cm/s] 8.7 ± 1.73 7.0 ± 0.91 0.0001
S’lat [cm/s] 10.24 ± 2.48 9.23 ± 1.12 0.03
PWDd [mm] 9.8  ± 1.3 9.8 ± 1.4 0.86
IVSDd [mm] 11.1 ± 0.9 11.4 ± 2.3 0.56
Ejection fraction [%] 65.9 ± 5.7 64.4 ± 6.4 0.31
E/E’ 8.2 ± 3.3 9.1 ± 3.2 0.22
4ch — four chamber; SV — stroke volume; LVEDV — left ventricular end-diastolic volume; LVESV — left ventricular end-systolic volume; other 
abbreviations — see text
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25 CRC patients (nine women) with normal baseline ECG and 
vital parameters treated with 5-FU. No changes in ECG, BP, 
or heart rate were noted. Echocardiography findings (LVEDD, 
LV mass) remained unaffected both after six cycles of 5-FU 
and six months after completion of CTX.
The most commonly reported in literature ECG changes 
provoked by 5-FU and capecitabine involve ST segment 
elevation or depression and/or T wave inversion whereas 
arrhythmias are not typically observed. In our study in three 
cases ECG showed T-wave inversion at baseline and during 
the observation period.
Similarly to Balloni’s findings, [8] none of our patients 
experienced any ECG abnormalities. Grandi et al. [11], on 
the other hand, did identify adverse effects of 5-FU on the 
cardiovascular system in 16 CRC patients (age 39–74) with 
initially normal BP, ECG, and echocardiogram. Transient T wave 
inversion without concomitant angina or myocardial necrosis 
markers elevation was registered in one patient during the first 
cycle of CTX and in another during the fifth cycle. Subsequently 
performed dipyridamole myocardial perfusion scintigraphy was 
normal in both of these patients. No other deviations in BP, heart 
rate, LVEDD, and LV mass index were registered throughout 
a six-month follow-up. No influence of CTX on mean systolic BP, 
diastolic BP, and resting heart rate was found during 12-month 
follow-up of our patients. Similarly, Grandi et al. [11] did not 
observe any changes of BP in CRC patients during treatment 
with 5-FU, nor six months after its completion.
Transient QT prolongation was observed regardless of 
CTX regimen in the third month (trend; not significant) and 
reached statistical significance in the sixth month (Table 4). 
Most available papers report QTc prolongation during CTX 
as soon as in the third month of follow-up. Some authors 
reported altered QT dispersion and QTc increase even during 
the first cycle of CTX.  
Our findings are consistent with these reports; addition-
ally, our data suggest that after CTX regimen termination QT 
returns to baseline. Although none of our subjects experienced 
clinically relevant arrhythmia (mean QT in the sixth month was 
still < 400 ms; only 5/25 patients [20%] had QT > 400 after 
six months), it is important to pay attention to patients with 
prolonged or borderline QT at baseline. 
Patients treated with pyrimidine analogues (5-FU or 
capecitabine) may experience angina pectoris, and acute 
coronary syndrome may be recognised especially if previously 
they have been diagnosed with ischaemic heart disease. It 
should be remembered that additional ECG abnormalities 
and arrhythmias may be observed [12]. Our study presents 
new findings that QT prolongation is possible, and changes in 
E’sept as well as in S’IVS and S’lat may occur. Of note, myo-
cardial velocities in the studied group were slightly decreased 
at baseline, and deteriorated over the observation period. 
The available literature has reported cases of takotsubo 
cardiomyopathy related to 5-FU or capecitabine [13, 14]. 
There are known published cases on cardiac conduction 
disturbances induced by 5-FU or capecitabine [15]. The 
cardiotoxic effects of these drugs seem to be multifactorial 
[16]. The suggested phenomenon of vasospasm induced by 
5-FU or capecitabine cannot explain the possibility of cardio-
myopathy, sinoatrial and atrioventricular node dysfunction, 
takotsubo cardiomyopathy, and QT prolongation with torsade 
de pointes ventricular tachycardia [17]. Although a recent 
European Society of Cardiology statement on cardiovascular 
toxicity of cancer treatment emphasises the ischaemic effect 
of 5-FU [18], cardiotoxicity of pyrimidines seems to have 
numerous mechanisms, including apoptosis of myocardium, 
depletion of high-energy phosphate compounds, increased 
oxygen consumption, impaired antioxidant defence system, 
and more [16].
Our findings confirm that further analyses of cardiac ef-
fects of pyrimidine analogues are needed with use of modern 
imaging of the cardiovascular system. 
We were unable to identify any other study describing 
local myocardial function in CRC patients receiving CTX, 
and therefore our findings of regional alterations of myocar-
dial velocities require further validation in expanded patient 
populations as well as prolonged follow-up to establish their 
transient or persistent character.
Limitations of the study
The number of included patients is relatively small but simi-
lar to previously published papers related to cardiovascular 
aspects of 5-FU therapy [8, 9]. Regrettably, novel echocardio-
graphy tools such as three-dimensional imaging could be 
used only in selected patients due to the modest availability 
of advanced ultrasound systems and were therefore not in-
cluded in the analysis.
CONCLUSIONS
Chemotherapy with 5-FU or capecitabine in CRC patients 
does not affect conduction system, LV structural parameters, 
and systolic function measured by LVEF, nor is it associated 
with cardiovascular events during the subsequent 12 months. 
Chemotherapy with 5-FU or capecitabine in CRC patients 
may trigger subtle changes in myocardial performance, which 
are solely detectable by tissue Doppler echocardiography 
after 12 months.
Transient QT prolongation is observed during CTX and 
resolves after CTX cessation.
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Subkliniczna dysfunkcja lewej komory wykryta 
metodą doplera tkankowego u pacjentów  
poddanych chemioterapii stosowanej  
w raku jelita grubego: wieloośrodkowe  
badanie ONCOECHO
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S t r e s z c z e n i e
Wstęp: Rak jelita grubego (CRC) jest jednym z najczęściej występujących nowotworów na świecie. W Polsce znajduje się 
na trzeciej pozycji wśród mężczyzn oraz na drugiej pozycji wśród kobiet pod względem zachorowań na nowotwory. Rola 
chemioterapii w leczeniu CRC zależy od stopnia zaawansowania nowotworu. Chemioterapię uzupełniającą stosuje się zawsze 
w III stopniu zaawansowania, a także w II stadium zaawansowania klinicznego przy obecności czynników ryzyka.
Cel: Celem niniejszej pracy była ocena występowania wczesnych powikłań sercowych u chorych włączonych do badania 
ONCOECHO w latach 2012–2014, leczonych chemioterapią z powodu CRC. W ramach badania potencjalnej kardiotok-
syczności chemioterapii oceniano funkcję skurczową i rozkurczową mięśnia sercowego, zaburzenia rytmu i przewodzenia 
oraz występowanie niekorzystnych zdarzeń sercowo-naczyniowych.
Metody: Do 12-miesięcznej obserwacji włączono 25 pacjentów z CRC (12 kobiet, średnia wieku 61,3 roku [35–76 lat]), 
poddanych 6-miesięcznej chemioterapii adjuwantowej. Spośród badanych 13 chorych stosowało chemioterapię opartą na 
5-fluorouracylu (5-FU), a pozostałych 12 pacjentów — terapię w schemacie opartym na kapecytabinie. Ocenę przepro-
wadzono wyjściowo oraz w 3., 6. i 12. miesiącu od rozpoczęcia leczenia. Analiza obejmowała obecność zaburzeń rytmu 
i przewodzenia, funkcję skurczową i rozkurczową mięśnia sercowego oraz występowanie zdarzeń sercowo-naczyniowych.
Wyniki: Po 12 miesiącach obserwacji niektóre parametry czynności lewej komory (LV) (S’IVS, S’lat i E’sept) uległy pogorszeniu. 
Frakcja wyrzutowa (EF) i wymiary jam serca pozostały niezmienione. Zmiany parametrów LV uwidocznione metodą doplera 
tkankowego po 12 miesiącach były niezależne od stosowanego schematu chemioterapii; nie wykazano również zależności 
między zmianami tych parametrów a stosowaniem inhibitorów konwertazy angiotensyny i beta-adrenolityków.
Wnioski: Stosowanie chemioterapii w CRC nie wpływa na parametry strukturalne ani klasyczne parametry czynności skur-
czowej LV (LVEF). Może jednak wywoływać subtelne pogorszenie zarówno czynności skurczowej, jak i rozkurczowej mięśnia 
sercowego wykrywalne przy użyciu doplera tkanowego po 12 miesiącach obserwacji, a także przejściowe wydłużenie odcinka 
QT ustępujące po zakończeniu chemioterapii.
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